NCT00161681View on ClinicalTrials.gov

Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS

PHASE3CompletedINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

August 31, 2006

Study Completion Date

August 31, 2006

Conditions
Premenstrual Syndrome
Interventions
DRUG

Levonorgestrel/Ethinyl Estradiol

Trial Locations (48)

14609

Rochester

15090

Wexford

15206

Pittsburgh

19104

Philadelphia

23226

Richmond

27103

Winston-Salem

28304

Fayetteville

29464

Mt. Pleasant

29926

Hilton Head Island

30328

Atlanta

30342

Atlanta

31406

Savannah

32720

DeLand

33024

Pembroke Pines

33143

Miami

33180

Aventura

33186

Miami

33407

West Palm Beach

33437

Boynton Beach

33607

Tampa

33761

Clearwater

33916

Fort Myers

35801

Huntsville

37203

Nashville

40509

Lexington

44122

Cleveland

44260

Mogadore

60612

Chicago

60631

Chicago

64114

Kansas City

77024

Houston

78229

San Antonio

80202

Denver

80501

Longmont

83404

Idaho Falls

84070

Sandy City

85031

Phoenix

85032

Phoenix

85381

Peoria

85715

Tucson

89109

Las Vegas

89118

Las Vegas

92103

San Diego

97401

Eugene

97504

Medford

98105

Seattle

98499

Lakewood

08057

Moorestown

All Listed Sponsors
lead

Wyeth is now a wholly owned subsidiary of Pfizer

INDUSTRY

NCT00161681 - Study Evaluating Levonorgestrel/Ethinyl Estradiol (LNG/EE) in PMS | Biotech Hunter | Biotech Hunter